Zobrazeno 1 - 10 of 824 pro vyhledávání: '"B. Livingston"'
1
Akademický článek
Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma
Autor: Megan H. Jagosky, Colin J. Anderson, James T. Symanowski, Nury M. Steuerwald, Carol J. Farhangfar, Emily A. Baldrige, Jennifer H. Benbow, Michael B. Livingston, Joshua C. Patt, Will A. Ahrens, Jeffrey S. Kneisl, Edward S. Kim
Publikováno v: Cancer Medicine, Vol 12, Iss 6, Pp 7029-7038 (2023)
Abstract Purpose Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options. Experimental Design Patients treated at Levine Cancer Institut
Externí odkaz: https://doaj.org/article/7e061913e58d4d3093d3ab4b289a48b5
Zobrazit plný text záznamu
2
Akademický článek
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Autor: Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki
Publikováno v: Cancer Medicine, Vol 12, Iss 2, Pp 1532-1539 (2023)
Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm,
Externí odkaz: https://doaj.org/article/124378635bd247fb9b2242a52cc12063
Zobrazit plný text záznamu
3
Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma
Autor: Megan H, Jagosky, Colin J, Anderson, James T, Symanowski, Nury M, Steuerwald, Carol J, Farhangfar, Emily A, Baldrige, Jennifer H, Benbow, Michael B, Livingston, Joshua C, Patt, Will A, Ahrens, Jeffrey S, Kneisl, Edward S, Kim
Publikováno v: Cancer Medicine. 12:7029-7038
Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options.Patients treated at Levine Cancer Institute with DDLPS were identified. Next gen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987f34a322de0cc7dffc986d5ebe7bf4
https://doi.org/10.1002/cam4.5502
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje